Abstract: When the soft-switching three-phase inverter is applied in transformerless photovoltaic (PV) systems, its common-mode (CM) leakage current has to be suppressed to satisfy grid codes. However ...

Sanofi has reported mixed phase 3 data on amlitelimab, further muddying the prospects of a molecule tipped to generate blockbuster sales. But, with hits among the misses, the French drugmaker plans to ...

Secretary Marco Rubio insisted the U.S. has a plan for post-transition governing in Venezuela, pushing back on criticism from Democrats who say the Trump administration moved faster to capture leader ...

WASHINGTON, Jan 7 (Reuters) - The U.S. has a three-step plan for Venezuela that will begin with stabilizing the country after U.S. forces seized leader Nicolas Maduro on Saturday, ensuring U.S. oil ...

Blue Origin’s New Glenn rocket at liftoff during the NG-2 mission on Nov. 13. Credit: Blue Origin The U.S. Space Force is now taking proposals from new launch providers with rockets ready to fly by ...

The cytokine A proliferation-inducing ligand (APRIL) is considered a key driver of the pathogenesis of IgA nephropathy. Sibeprenlimab, a humanized IgG2 monoclonal antibody, selectively binds to and ...

At the Renewable Energy India (REI) Expo 2025, Waaree Energies introduced a new three-phase inverter designed for utility-scale solar installations. The inverter prioritizes data privacy and supports ...

The three phase string inverter market is on a transformative growth path, reflecting the global acceleration toward renewable energy adoption, improved grid stability, and advanced power conversion ...

Loom Solar has introduced the Fusion 103H three-phase 10 kW/48 V hybrid inverter that combines the functions of a solar inverter and a battery inverter in a single device. The wall-mounted inverter is ...

TPAO has awarded additional contracts for additional development of Sakarya gas field in the Black Sea. Phase 3 involves a new floating production unit, 27 wells, and a 183-km export pipeline ...

Regeneron is racing to regulators after reporting a phase 3 win in an ultrarare disease. The biotech plans to file for FDA approval of garetosmab in fibrodysplasia ossificans progressiva (FOP) by the ...